Study study type PathologyT1T0Patientssample sizesROB Results

Extensive stage SCLC (Es-SCLC) - maintenance (M) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - maintenance (M)

versus placebo
nivolumab plus ipilimumab
CheckMate 451 (NI ; all population), 2019
  NCT02538666
RCTExtensive stage SCLC (Es-SCLC) - maintenance (M)nivolumab plus ipilimumabplacebopatients with extensive-stage disease small cell lung cancer (ED-SCLC) as maintenance therapy after completion of platinum-based chemotherapy279 / 275some concern
inconclusive
  • inconclusive 8 % decrease in deaths (OS) (PE)
  • suggested 28 % decrease in progression or deaths (PFS)

Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)

versus etoposide plus platin
durvalumab plus tremelimumab plus SoC
CASPIAN (DT ; all population), 2019
  NCT03043872
RCTExtensive stage SCLC (Es-SCLC) - 1st Line (L1)durvalumab plus tremelimumab and etoposide plus either cisplatin or carboplatinetoposide plus either cisplatin or carboplatinadults with untreated extensive-stage small-cell lung cancer (SCLC)268 / 269some concern
inconclusive
  • inconclusive 18 % decrease in deaths (OS) (PE)